JP2024534499A - Il5ra細胞表面マーカー - Google Patents

Il5ra細胞表面マーカー Download PDF

Info

Publication number
JP2024534499A
JP2024534499A JP2024517427A JP2024517427A JP2024534499A JP 2024534499 A JP2024534499 A JP 2024534499A JP 2024517427 A JP2024517427 A JP 2024517427A JP 2024517427 A JP2024517427 A JP 2024517427A JP 2024534499 A JP2024534499 A JP 2024534499A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
recombinant polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534499A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ マッセイ,
ジョシュア バイルケ,
トレバー ミラー,
Original Assignee
ソノマ バイオセラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソノマ バイオセラピューティクス, インコーポレイテッド filed Critical ソノマ バイオセラピューティクス, インコーポレイテッド
Publication of JP2024534499A publication Critical patent/JP2024534499A/ja
Publication of JP2024534499A5 publication Critical patent/JP2024534499A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024517427A 2021-09-22 2022-09-22 Il5ra細胞表面マーカー Pending JP2024534499A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247239P 2021-09-22 2021-09-22
US63/247,239 2021-09-22
PCT/US2022/076862 WO2023049803A1 (en) 2021-09-22 2022-09-22 Il5ra cell surface markers

Publications (2)

Publication Number Publication Date
JP2024534499A true JP2024534499A (ja) 2024-09-20
JP2024534499A5 JP2024534499A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85721256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517427A Pending JP2024534499A (ja) 2021-09-22 2022-09-22 Il5ra細胞表面マーカー

Country Status (9)

Country Link
US (1) US20240417443A1 (cg-RX-API-DMAC7.html)
EP (1) EP4405383A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534499A (cg-RX-API-DMAC7.html)
KR (1) KR20240069766A (cg-RX-API-DMAC7.html)
CN (2) CN118251407A (cg-RX-API-DMAC7.html)
AU (1) AU2022349077A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232203A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003250A (cg-RX-API-DMAC7.html)
WO (1) WO2023049803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121538180A (zh) * 2025-11-28 2026-02-17 中国医学科学院肿瘤医院 经修饰的单核细胞、其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533998A (ja) * 2000-05-22 2003-11-18 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー レセプターを用いた相互作用の捕捉法
JP2020527937A (ja) * 2017-06-07 2020-09-17 プレシゲン,インコーポレイテッド 新規の細胞タグの発現

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
HK1255922A1 (zh) * 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
IL296242A (en) * 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for generating engineered memory-like nk cells and compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533998A (ja) * 2000-05-22 2003-11-18 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー レセプターを用いた相互作用の捕捉法
JP2020527937A (ja) * 2017-06-07 2020-09-17 プレシゲン,インコーポレイテッド 新規の細胞タグの発現

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Interleukin-5 receptor subunit alpha", UNIPROTKB/SWISS-PROT[ONLINE],[検索日 2026.06.19], RETRIEVED FROM THE INTERNET, JPN6026027145, 2 June 2021 (2021-06-02), ISSN: 0005895038 *
BLOOD, vol. Vol. 118,No. 5,p.1255-1263, JPN6026027149, 2011, ISSN: 0005895042 *
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. Vol. 25,No. 7,p.1857-1864, JPN6026027142, 1995, ISSN: 0005895035 *
FRONTIERS IN ENDOCRINOLOGY, vol. Vol. 8,Article 71, JPN6026027146, 18 April 2017 (2017-04-18), ISSN: 0005895039 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol. 279,No. 10,p.9547-9556, JPN6026027147, 2004, ISSN: 0005895040 *
RESPIRATORY MEDICINE, vol. Vol. 160, 2019, 105819, JPN6026027144, November 2019 (2019-11-01), ISSN: 0005895037 *
SCIENCE, vol. Vol. 293,No. 5532,p.1136-1138, JPN6026027143, 2001, ISSN: 0005895036 *
THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. Vol. 180,No. 6,p.2101-2111, JPN6026027148, 1994, ISSN: 0005895041 *

Also Published As

Publication number Publication date
US20240417443A1 (en) 2024-12-19
MX2024003250A (es) 2024-05-28
CN118251407A (zh) 2024-06-25
EP4405383A4 (en) 2025-08-20
KR20240069766A (ko) 2024-05-20
CA3232203A1 (en) 2023-03-30
WO2023049803A1 (en) 2023-03-30
CN119661725A (zh) 2025-03-21
EP4405383A1 (en) 2024-07-31
AU2022349077A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
JP6499245B2 (ja) 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
CN111836827B (zh) 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
EP3025719B1 (en) Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CN112771154B (zh) 含有nef的t细胞及其产生方法
EP3577134A1 (en) Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN110511912B (zh) 免疫细胞的功能调节
WO2020018708A1 (en) Compositions and methods for treatment of t cell malignancies
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
JP2021536245A (ja) 血液中または濃縮pbmc中のリンパ球を遺伝子改変するための方法および組成物
CN111440813A (zh) 基于合成生物学的新型adcc技术
WO2022098750A1 (en) Hla class ii-restricted tcrs against the kras g12>v activating mutation
US20250297022A1 (en) Engineered switches for immune cell activity and methods of use thereof
WO2020018691A1 (en) Modified t cells and methods of their use
WO2018111340A1 (en) Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP4041410A2 (en) Engineered trimeric cd70 proteins and uses thereof
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
US20240417443A1 (en) Il5ra cell surface markers
CN118679261A (zh) 经修饰的细胞及其用途
KR20240034205A (ko) 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
US20250319130A1 (en) Recombinant receptors binding b cell activation factor receptor and uses thereof
WO2025207642A1 (en) Cxcr3 isoforms to improve recombinant receptor trafficking
WO2025212536A1 (en) Therapeutic antibody epitope-tagged car t cells for enhanced control and safety
KR20240035506A (ko) 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260626